Abstract
The dynamics of innate and adaptive immunity to infection in infants remain obscure. Here, we used a multi-omics approach to perform a longitudinal analysis of immunity to SARS-CoV-2 infection in infants and young children in the first weeks and months of life by analyzing blood samples collected before, during, and after infection with Omicron and Non-Omicron variants. Infection stimulated robust antibody titers that, unlike in adults, were stably maintained for >300 days. Antigen-specific memory B cell (MCB) responses were durable for 150 days but waned thereafter. Somatic hypermutation of V-genes in MCB accumulated progressively over 9 months. The innate response was characterized by upregulation of activation markers on blood innate cells, and a plasma cytokine profile distinct from that seen in adults, with no inflammatory cytokines, but an early and transient accumulation of chemokines (CXCL10, IL8, IL-18R1, CSF-1, CX3CL1), and type I IFN. The latter was strongly correlated with viral load, and expression of interferon-stimulated genes (ISGs) in myeloid cells measured by single-cell transcriptomics. Consistent with this, single-cell ATAC-seq revealed enhanced accessibility of chromatic loci targeted by interferon regulatory factors (IRFs) and reduced accessibility of AP-1 targeted loci, as well as traces of epigenetic imprinting in monocytes, during convalescence. Together, these data provide the first snapshot of immunity to infection during the initial weeks and months of life.
Competing Interest Statement
Alessandro Sette is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group and Guggenheim. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work.
Funding Statement
This work was supported by NIH grants U01 AI144673-01 (principal investigator M.A.S.). Work in the laboratory of B.P. is supported in part by the NIH (R01 AI048638, U19 AI057266 and U19 AI167903), Bill and Melinda Gates Foundation, Open Philanthropy and the Violetta L. Horton and Soffer Endowments to B.P. F.W. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) grants EXC2180-390900677 (Germany's excellence strategy) and 503745673 (Emmy Noether Program). The sequencing data at Stanford were generated with instrumentation purchased with NIH funds (S10OD025212 and 1S10OD021763). Next-generation sequencing services were provided by the Emory NPRC Genomics Core, which is supported in part by NIH P51 OD011132. Sequencing data were acquired on an Illumina NovaSeq6000 funded by NIH S10 OD026799. The antibody neutralization work described in this manuscript was supported by FDA's MCMi grant #OCET 2021-1565 and FDA's Perinatal Health Center of Excellence (PHCE) project grants #GCBER005 and GCBER008 to S.K. The autoantibody work was supported by NIHs funds (R01 AI125197, RECOVER OTA-21-15B, and R38 HL143615) and philanthropic support from the Sean N Parker Center COVID-19 Research Fund and the Henry Gustav Floren Trust. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.G. and 75N9301900065 to A.S. The funders had no role in study design, data collection, analysis, interpretation, writing, the decision to publish, or preparation of the manuscript. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received approval from the appropriate Institutional Review Board at Emory (#00022371) and Stanford (#55689) University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The single-cell multi-omics and bulk transcriptomics data are currently being submitted to the Gene Expression Omnibus (GEO) and will be publicly available at the time of publication.
